<DOC>
	<DOCNO>NCT02479399</DOCNO>
	<brief_summary>The objective survey confirm safety Suglat Tablets</brief_summary>
	<brief_title>Specified Drug Use Results Survey Ipragliflozin Treatment type2 Diabetes Patients</brief_title>
	<detailed_description>The objective survey confirm safety efficacy Suglat Tablets long-term use 3 year . Specify effect Suglat Tablets cardiovascular system , incidence rate malignant tumor , risk factor . Investigate occurrence adverse drug reaction . Specify factor may possibly influence safety efficacy Suglat Tablets . &lt; Items interest &gt; - Hypoglycemia - Genital infection - Urinary tract infection - Polyuria pollakiuria - Adverse event related decrease body fluid ( dehydration , etc . ) - Malignant tumor - Cardiovascular disease</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<criteria>Patients type 2 diabetes first use Suglat Tablets period July 17 , 2014 July 16 , 2015 offlabel use patient</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Suglat</keyword>
	<keyword>SGLT-2 inhibitor</keyword>
	<keyword>Ipragliflozin L-Proline</keyword>
	<keyword>ASP1941 long-term use</keyword>
</DOC>